Results from a small study of
Low Dose Naltrexone (LDN) have been published in the
journal
Multiple Sclerosis. The study headed by Dr. Gianvito Martino from
the San Raffaele Hospital in Milan, Italy involved 40 people with
primary progressive MS in an
open label trial which aimed to make sure LDN was
safe and well tolerated.
The results show that LDN is safe for people
with MS. The trial also took an initial look at pain, fatigue, depression and
spasticity in people with MS and the results suggested a beneficial effect of
LDN on spasticity.
Dr Laura Bell, Research Communication Officer at the
MS Society said, 'As with all drugs, there is a long way to go in terms of
rigorous large scale clinical trials held over a number of years to determine if
LDN would be safe and more effective than treatments currently available. But
the results of this small pilot study is an important initial step and we await
results from further studies with interest.'
MS Society
